Astellas joins forces with Ambrx to develop antibody-drug conjugates

04/8/2013 | Genetic Engineering & Biotechnology News

Astellas Pharma and Ambrx agreed to collaborate in the discovery and development of antibody-drug conjugates for cancer using the latter's site-specific conjugation technology, linkers and drug payloads. Ambrx will get $15 million upfront plus as much as $285 million in milestone fees and sales royalties. The rights to further develop and market the ADCs will go to Astellas.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ